ClinicalTrials.gg
Active, not recruitingNCT06513312PURPOSE 5Updated Jun 15, 2026

Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)

A Phase 2 interventional study of Lenacapavir Injection and Lenacapavir Tablet in Pre-Exposure Prophylaxis of HIV Infection, sponsored by Gilead Sciences. Active, not recruiting at 14 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
268
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 84 studies in HIV Infections by Gilead Sciences — 2 open to participants now, 8 under way, 4 of them phase 3. HIV Infections · Gilead Sciences.

Enrollment
24th of 72
268 · median 131
Started
2024
the only one that year
Phase 2
16 of 84
none open now
Registered
82nd of 84
by date

Among the 84 studies in HIV Infections by Gilead Sciences, this one is the 24th largest by enrollment of the 72 interventional ones that give a count, is the only one that started in 2024, is one of 16 in phase 2, and was the 82nd registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

2 of the 84 studies in HIV Infections by Gilead Sciences are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in HIV Infections by Gilead Sciences, or all of them as a file.
02

Study summary

The goals of this clinical study are to learn more about the study drug lenacapavir (LEN), by comparing the consistent and continuous use of LEN and emtricitabine/tenofovir disoproxil fumarate (coformulated; Truvada®) (F/TDF), then by observing the safety of LEN and F/TDF, evaluating the acceptability of LEN injections and oral F/TDF, and observe how LEN moves throughout the body in people who would benefit from pre-exposure prophylaxis (PrEP).

The primary objective of this study is to compare LEN and F/TDF consistent and continuous use among people who would benefit from PrEP.

03

Conditions studied

  • Pre-Exposure Prophylaxis of HIV Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Able to comprehend and provide a signed written , which must be obtained prior to initiation of study procedures.
  • Cisgender men who have sex with men, transgender women, transgender men, cisgender women, and nonbinary people.
  • Increased likelihood of acquisition as indicated by at least one of the following:

    1. Condomless sex with ≥ 2 partners in the past 6 months
    2. Diagnosis of a bacterial sexually transmitted infection (STI) in the past 12 months
    3. Engagement in sex work or transactional sex in the past 12 months
    4. Use of ≥ 2 courses of nonoccupational HIV post-exposure prophylaxis (nPEP) in the past 12 months
    5. Condomless sex with a partner living with HIV who has unknown or unsuppressed viral load (≥ 200 copies/mL) in the past 12 months
  • Negative local rapid HIV-1/2 antibody (Ab)/antigen (Ag) test, central HIV-1/2 Ab/Ag, and HIV-1 RNA quantitative nucleic acid amplification testing (NAAT) at screening.

    1) If rapid HIV-1/2 Ab/Ag tests are unavailable due to extenuating circumstances, sites may run a laboratory-instrumented HIV-1/2 Ab/Ag test at their local laboratory, only if they confirm this is a fourth-generation assay and the time from blood draw to injection at any injection visit is \< 48 hours.

  • Estimated (GFR) at least 60 mL/min at screening according to the formula for creatinine clearance (CLcr):

    • (140 - age in years) × (weight in kg) x (0.85 if female) = CLcr (mL/min) / 72 × (serum creatinine in mg/dL)

Key Exclusion Criteria:

  • Coenrollment in any other clinical study (including observational) without prior approval from the sponsor is prohibited while participating in this study.
  • Known to the study drug, the metabolites, or formulation .
  • Current use of PrEP, defined as the use of PrEP in the preceding 4 weeks. PrEP should not be discontinued to facilitate study participation. For cabotegravir, this is defined as 4 weeks since the next injection was due (ie, 12 weeks since their most recent cabotegravir injection).
  • Current use of nPEP, unless the prescribed course will be completed prior to randomization.
  • Past or current participation in HIV vaccine or HIV broadly neutralizing Ab study unless participant provides documentation of receipt of placebo (ie, not active product).
  • Acute viral hepatitis A, B, or C or evidence of chronic or C infection
  • Severe hepatic impairment or a history of or current clinical decompensated liver cirrhosis (eg, ascites, encephalopathy, variceal bleeding).
  • Have a suspected or known active, serious infection(s) (eg, active tuberculosis, etc).

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
268 participants (actual)

Study arms

  • Experimental
    Randomized Phase: Lenacapavir (LEN) Group

    Participants will receive subcutaneous (SC) LEN 927 mg on Day 1 and 26 weeks and oral LEN 600 mg on Day 1 and 2.

    Drug: Lenacapavir Injection · Drug: Lenacapavir Tablet

  • Active comparator
    Randomized Phase: F/TDF

    Participants will receive daily F/TDF (200/300 mg) fixed dose combination (FDC) tablets for up to 52 weeks.

    Drug: Emtricitabine/tenofovir disoproxil fumarate (F/TDF)

  • Experimental
    LEN Open Label Extension (OLE) Phase

    Participants in the F/TDF group will transition to get LEN and participants in the LEN group will continue to get LEN. All participants will get SC LEN on Day 1 and week 26 of the OLE phase.

    Drug: Lenacapavir Injection · Drug: Lenacapavir Tablet

  • Experimental
    Pharmacokinetic (PK) Tail Phase: F/TDF

    After completion of the LEN OLE Phase or upon discontinuation from the Randomized Phase for those receiving LEN, participants will be transitioned to receive F/TDF in the PK Tail Phase. Participants will receive once daily F/TDF for 78 weeks, beginning 26 weeks after the last LEN injection

    Drug: Emtricitabine/tenofovir disoproxil fumarate (F/TDF)

Interventions

  • Administered subcutaneously

    Also known as: GS-6207, Yeztugo®

  • Administered orally

    Also known as: GS-6207

  • DrugEmtricitabine/tenofovir disoproxil fumarate (F/TDF)

    Administered orally

    Also known as: Truvada®

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with LEN and F/TDF Persistence through 52 Weeks

    This outcome measure will compare LEN and F/TDF persistence through 52 weeks, where persistence is defined by On-time LEN Injection at Day 1/Baseline and Week 26 and On-time Follow-up Visit at Week 52 for LEN arm and by Adherence Levels Based on tenofovir diphosphate (TFV-DP) concentrations in red blood cells consistent with ≥ 4 doses/week (≥ 700 fmol/punch) in dried blood spot (DBS) at Weeks 13, 26, 39, and 52 for F/TDF arm.

    Time frame: Up to Week 52

Secondary outcomes

  1. Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

    Time frame: First dose date up to 30 days post last dose at Week 78

  2. Percentage of Participants Experiencing Treatment-emergent Clinical Laboratory Abnormalities

    Time frame: First dose date up to 30 days post last dose at Week 78

  3. Overall acceptability of LEN and F/TDF as PrEP as Assessed by Percentage of Participants with responses to Question on Acceptability

    To assess the acceptability of the study drug, participants will complete the questionnaire including a question on general acceptability of the assigned study drug on an ordinal 5-category scale with a response of: Completely unacceptable, Unacceptable, No opinion, Acceptable, or Completely acceptable.

    Time frame: Up to Week 52

  4. Pharmacokinetic (PK) Parameter: Ctrough for LEN at Week 26

    Ctrough is defined as the concentration at the end of the dosing interval.

    Time frame: Week 26

  5. PK Parameter: Ctrough for LEN at Week 52

    Ctrough is defined as the concentration at the end of the dosing interval.

    Time frame: Week 52

07

Study locations

14 sites
  • Hopital Avicenne
    Bobigny, 93000, France
  • Hopital Europeen Marseille
    Marseille, 13006, France
  • CHU Nice Archet
    Nice, 6202, France
  • Hopital Saint Louis - Assistance Publique des Hopitaux de Paris
    Paris, 75010, France
  • APHP Hopital Saint-Antoine
    Paris, 75012, France
  • APHP Bichat Claude-Bernard Hospital
    Paris, 75018, France
  • University Hospitals Birmingham NHS Foundation Trust, Birmingham Heartlands Hospital
    Birmingham, B9 5SS, United Kingdom
  • Clinical Research Facility, University Hospitals Sussex NHS Foundation Trust
    Brighton, BN2 3EW, United Kingdom
  • Axess Sexual Health, Liverpool University Hospitals NHS Trust
    Liverpool, L7 8YE, United Kingdom
  • Grahame Hayton Unit, Ambrose King Centre, Royal London Hospital, Barts Health NHS Trust
    London, E11BB, United Kingdom
  • Homerton Healthcare NHS Foundation Trust, Homerton University Hospital
    London, E9 6SR, United Kingdom
  • Caldecot Centre, Kings College Hospital, Kings College Hospital NHS Foundation Trust
    London, SE5 9RS, United Kingdom
  • Chelsea and Westminster Hospital NHS Foundation Trust, Clinical Research Facility, Chelsea and Westminster Hospital
    London, SW10 9NH, United Kingdom
  • Manchester University NS Foundation Trust
    Manchester, M13 0FH, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in May 2026, 19 months.

Of 34 industry-sponsored phase 2 interventional studies under HIV Infections, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 19 months is close to that.

Counting every sponsor, half of 99 studies reached it within 31 months; a quarter within 17 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2024
First posted
Jul 22, 2024
StartActual
Oct 7, 2024
Primary completionActual
May 28, 2026
CompletionEst.
Nov 2028
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06513312
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jul 22, 2024
Start date
Oct 7, 2024
Primary completion
May 28, 2026
Completion
Nov 2028 (estimated)
Last update
Jun 15, 2026

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenacapavir

Start the discussion